Suzuki, T., Mizoshita, T., Sugiyama, T., Hirata, Y., Kimura, Y., Suzuki, Y., . . . Sasaki, M. (2019). Adalimumab Dose-Escalation Therapy Is Effective in Refractory Crohn's Disease Patients with Loss of Response to Adalimumab, Especially in Cases without Previous Infliximab Treatment. Case Rep Gastroenterol.
Chicago-stil citatSuzuki, Taketo, et al. "Adalimumab Dose-Escalation Therapy Is Effective in Refractory Crohn's Disease Patients With Loss of Response to Adalimumab, Especially in Cases Without Previous Infliximab Treatment." Case Rep Gastroenterol 2019.
MLA-referensSuzuki, Taketo, et al. "Adalimumab Dose-Escalation Therapy Is Effective in Refractory Crohn's Disease Patients With Loss of Response to Adalimumab, Especially in Cases Without Previous Infliximab Treatment." Case Rep Gastroenterol 2019.